Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies

A Fayaz,1 P Croft,2 R M Langford,3 L J Donaldson,4 G T Jones5

ABSTRACT
Objectives: There is little consensus regarding the burden of pain in the UK. The purpose of this review was to synthesise existing data on the prevalence of various chronic pain phenotypes in order to produce accurate and contemporary national estimates.

Design: Major electronic databases were searched for articles published after 1990, reporting population-based prevalence estimates of chronic pain (pain lasting >3 months), chronic widespread pain, fibromyalgia and chronic neuropathic pain. Pooled prevalence estimates were calculated for chronic pain and chronic widespread pain.

Results: Of the 1737 articles generated through our searches, 19 studies matched our inclusion criteria, presenting data from 139 933 adult residents of the UK. The prevalence of chronic pain, derived from 7 studies, ranged from 35.0% to 51.3% (pooled estimate 43.5%, 95% CIs 38.4% to 48.6%). The prevalence of moderate-severely disabling chronic pain (Von Korff grades III/IV), based on 4 studies, ranged from 10.4% to 14.3%. 12 studies stratified chronic pain prevalence by age group, demonstrating a trend towards increasing prevalence with increasing age from 14.3% in 18–25 years old, to 62% in the over 75 age group, although the prevalence of chronic pain in young people (18–39 years old) may be as high as 30%. Reported prevalence estimates were summarised for chronic widespread pain (pooled estimate 14.2%, 95% CI 12.3% to 16.1%; 5 studies), chronic neuropathic pain (8.2% to 8.9%; 2 studies) and fibromyalgia (5.4%; 1 study). Chronic pain was more common in female than male participants, across all measured phenotypes.

Conclusions: Chronic pain affects between one-third and one-half of the population of the UK, corresponding to just under 28 million adults, based on data from the best available published studies. This figure is likely to increase further in line with an ageing population.

INTRODUCTION
Chronic pain, represented by conditions such as low back pain and osteoarthritis, has recently been highlighted as one of the most prominent causes of disability worldwide by the Global Burden of Disease reviews.1 At the same time, national governments have started to recognise that chronic pain represents a major priority and challenge for their public health and healthcare systems through production of national strategies and convening of Pain Summits in countries including the UK, the USA and Australia.2–5 Such initiatives emphasise the importance of accurate population-based estimates of chronic pain in helping to drive and inform policies of prevention and care, needs assessments, and surveillance of the impact of interventions, as has happened for other long-term conditions such as cancer and cardiovascular disease.

Despite several high profile national reports highlighting the significance of chronic pain in the UK,5–8 there is little consensus regarding the burden of pain in this country. One estimate suggests that up to 8 million people in the UK live with chronic pain,9 in keeping with a telephone survey of residents across Europe in which 13% of the UK population reported pain of moderate-to-severe intensity, lasting for a period of >6 months.9 Estimates based on definitions more closely aligned with that of the International Association of the Study of Pain: ‘pain that persists beyond normal tissue healing time, which is assumed to be 3 months’10 have been considerably higher than those quoted from the European
telephone survey. The purpose of this review was to synthesise existing data on the population prevalence of various chronic pain definitions, in order to produce much needed, accurate and contemporary national estimates.

METHODS

A protocol for the review was devised in accordance with the PRISMA guidelines and registered on PROSPERO (CRD: 42014012993). Searches of MEDLINE (inception to 31 May 2015) and EMBASE (1980 to 31 May 2015) electronic databases were performed (via Ovid) for articles reporting the prevalence of chronic pain in the UK. A list of the medical subject headings and free-text terms used are included under online supplementary appendix A. The results were supplemented by a manual search of the bibliographies of the shortlisted review and original study articles. In addition, a number of field experts were approached in order to identify additional viable studies from the grey literature.

We included all study formats reporting any point or period prevalence estimates, from a general population sample, for the following: (1) chronic pain: defined as pain in one or more body locations, lasting for a period of 3 months or longer; (2) chronic widespread pain: defined in accordance with the American College of Rheumatology (ACR) 1990 guidelines as pain in the axial skeleton and two contralateral limbs, lasting for a period of 3 months or longer; (3) fibromyalgia: defined in relation to either the 1990 or 2010 ACR criteria as ‘widespread’ pain, lasting for a period of 3 months or longer, in association with tender points or somatic symptoms as described in their respective protocols; and (4) neuropathic pain: defined as pain in one or more body locations, lasting for a period of 3 months or longer, with predominantly neuropathic features. Studies presenting data relating exclusively to specific cohorts were incorporated into a meta-analysis. The SEs for prevalence (p) estimates were derived from the equation \[
\sqrt{\frac{(p \times (1 - p))/n)}{n}},
\]
where n=number of participants with completed data in survey. Data were synthesised using StataSE V.13 for Mac. Studies were weighted according to the prevalence effect size and the inverse of the study variance in order to generate an I² value, serving as a measure of heterogeneity among the studies. A random effects model was used to generate summary prevalence data, displayed (on forest plots) with 95% CIs. Where number of studies and variation in the characteristics was sufficient (calendar year of survey and geographical location), stratified analysis of the survey prevalence figures was presented.

RESULTS

After removal of duplicates, our initial search generated 1726 studies. From this cohort 87 full-text articles were
reviewed for eligibility assessment; a further 11 articles were identified from the additional searches described in the Methods section. Flow charts of the screening and selection processes are included below under online supplementary appendices B and C.

Of the 25 papers shortlisted for detailed analysis, 6 were excluded on the basis of high risk of bias. Articles were mainly excluded due to the use of non-standardised definitions of chronic pain phenotypes, (case definition and period prevalence risk) or from surveying populations that were deemed to be unrepresentative of the general population (study population and sampling frame risk). A breakdown of the risk of bias scoring, for included and excluded articles is presented under online supplementary appendix D.

In total, 19 articles were included for synthesis in our review: 13 cross-sectional studies, 4 cohort studies and 2 case–control studies nested in population cohorts. Collectively, the articles present prevalence data on 139,933 residents of the UK; baseline characteristics of included studies are presented in table 1. Meta-analysis was possible for two of the study phenotypes, namely chronic pain and chronic widespread pain.

### Chronic pain

Ten studies presented prevalence data for chronic pain, two of which were from age-restricted cohorts and are therefore excluded from our national synthesis; a UK (England, Scotland and Wales) birth cohort of residents aged 45 years and a survey of 18–25 years old from the North Staffordshire region. One study drew participants from a cohort of women previously enrolled in a national study looking at the long-term effects of the contraceptive pill, and therefore did not present any pain prevalence data for males. The remaining seven articles reported data on general population samples from various regions across the UK, male participants comprised between 41.4% and 49.5% of the survey respondents. Reported prevalence of chronic pain in the UK ranged from 35.0% to 51.3% (table 2; pooled estimate 43.5%, 95% CI 38.4% to 48.5%). A forest plot of the estimates according to publication date suggests an increasing prevalence with age were demonstrated in studies looking at chronic widespread pain and neuropathic pain. Within studies, chronic pain prevalence increased steadily with age from a low of 14.3% in 18–25 years old to as high as 62% in the over 75 age group. A single exception to this trend was observed in one instance where reported pain prevalence among 50–64 years old was higher than that reported in the older age strata. Two of the five articles presenting data in the youngest age strata (18–39 years old) reported prevalence estimates >30%. The data for chronic pain have been tabulated in figure 3. Similar patterns of increasing prevalence with age were demonstrated in studies looking at chronic widespread pain and neuropathic pain, with one single exception where the prevalence of chronic widespread pain in 65–74 years old was lower than the prevalence in the 55–64-year-old bracket; stratification by gender in this study demonstrates that this drop is due to reduced pain reporting by male participants in the 65–74-year-old age bracket. The prevalence of chronic widespread pain ranged from 6.8% in 18–32 years old to a peak of 21% in the over 75 age group. Neuropathic pain prevalence by age was reported in a single study demonstrating increasing pain prevalence: 6.3%, 9.7% and 10.4% in 18–39, 40–59 and over 60 years old, respectively.

### Chronic pain severity

Four articles presented data on chronic pain prevalence in which estimates were stratified according to pain severity, using the ‘grading severity of chronic pain’ tool developed by Von Korff et al, and validated for use in chronic pain research. The data have been reproduced in table 3; the national prevalence of moderately limiting, high disability pain (grade III) ranged from 4.7% to 6.5%, and that of highly limiting, high disability pain (grade IV) from 5.7% to 7.8% of the total.
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Sample source</th>
<th>Sample size</th>
<th>Response rate (Corrected)*</th>
<th>Male (n)</th>
<th>Age range (mean)</th>
<th>Prevalence estimates included in systematic review</th>
<th>Method for data retrieval</th>
<th>Risk of bias</th>
<th>Primary aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beasley et al</td>
<td>Cross-sectional</td>
<td>2 GP practices in UK</td>
<td>14680†</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To see if the distribution of reported pain sites has any association with a number of potential risk markers</td>
</tr>
<tr>
<td>Macfarlane et al</td>
<td>Cohort</td>
<td>GB birth cohort</td>
<td>12069</td>
<td>78.0%</td>
<td>49.4% (3918)</td>
<td>45</td>
<td>♦</td>
<td>Interview and examination</td>
<td>Moderate</td>
<td>To determine to what extent the reporting of pain in adulthood varies by adult socioeconomic status</td>
</tr>
<tr>
<td>Gale et al</td>
<td>Cohort</td>
<td>GB birth cohort</td>
<td>11971</td>
<td>78.3%</td>
<td>49.2% (3399)</td>
<td>45 (45)</td>
<td>♦</td>
<td>Questionnaire</td>
<td>Low</td>
<td>To investigate the relationship between intelligence in childhood and risk of CWP in adulthood</td>
</tr>
<tr>
<td>Smith et al</td>
<td>Cross-sectional</td>
<td>UK RCP OCP study</td>
<td>11797</td>
<td>85.4%</td>
<td>0%</td>
<td>–</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To examine the prevalence and factors associated with CP among women still in the RCoGP OCP Study</td>
</tr>
<tr>
<td>Croft et al</td>
<td>Case Control nested in Cohort</td>
<td>UK RCP OCP study</td>
<td>11797</td>
<td>85.4%</td>
<td>(0)</td>
<td>(55)</td>
<td>♦</td>
<td>Questionnaire</td>
<td>Low</td>
<td>To identify associations between illness episodes and future pain complaints</td>
</tr>
<tr>
<td>Jones et al</td>
<td>Cohort</td>
<td>GB birth cohort</td>
<td>10453</td>
<td>89.7%</td>
<td>–</td>
<td>44–46 (45)</td>
<td>♦</td>
<td>Postal questionnaire</td>
<td>Low</td>
<td>To examine whether children with common symptoms experience an increased risk of CWP as adults</td>
</tr>
<tr>
<td>Torrance et al</td>
<td>Cross-sectional</td>
<td>10 GP practices, 5 locations across England and Scotland</td>
<td>10000</td>
<td>44.5% (47.0%)</td>
<td>42.9% (1846)</td>
<td>&gt;18 (53)</td>
<td>♦ ♦ ♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To estimate the proportion of NeP in the population, that is, ‘refractory’</td>
</tr>
<tr>
<td>Bridges</td>
<td>Cross-sectional</td>
<td>Case-control nested in cohort</td>
<td>8599†</td>
<td>(66.0%)</td>
<td>44.4% (3817)</td>
<td>16–100</td>
<td>♦ ♦ ♦ ♦</td>
<td>Interview</td>
<td>Moderate</td>
<td>To examine the relationship between diet and lifestyle, and CWP</td>
</tr>
<tr>
<td>Vandenkerkhof et al</td>
<td>Cross-sectional</td>
<td>UK Birth cohort (England, Scotland and Wales)</td>
<td>8572†</td>
<td>–</td>
<td>–</td>
<td>45 (45)</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To examine the relationship between diet and lifestyle, and CWP</td>
</tr>
<tr>
<td>Torrance et al</td>
<td>Cross-sectional</td>
<td>6 GP practices (Grampian, Leeds, London)</td>
<td>6000</td>
<td>50.0% (52.4%)</td>
<td>44.4% (1333)</td>
<td>18–96 (50)</td>
<td>♦ ♦ ♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To improve the understanding of chronic pain with neuropathic features using epidemiological research</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Sample source</th>
<th>Sample size</th>
<th>Response rate (Corrected)*</th>
<th>Male (n)</th>
<th>Age range (mean)</th>
<th>Prevalence estimates included in systematic review</th>
<th>Method for data retrieval</th>
<th>Risk of bias</th>
<th>Primary aim</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elliott et al</td>
<td>Cross-sectional</td>
<td>29 GP practices across Grampian, Scotland</td>
<td>5036</td>
<td>71.6% (82.3%) (1741)</td>
<td>48.3% (1471)</td>
<td>&gt;25</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Low</td>
<td>To quantify and describe the prevalence and distribution of CP in the community</td>
</tr>
<tr>
<td>Smith et al</td>
<td>Cross-sectional</td>
<td>29 GP practices across Grampian, Scotland</td>
<td>4611</td>
<td>78.2% (82.3%)</td>
<td>48.3%</td>
<td>&gt;25</td>
<td>♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To describe the prevalence and distribution in the community of CP defined as 'significant' and 'severe'</td>
</tr>
<tr>
<td>Jones et al</td>
<td>Cross-sectional</td>
<td>Grampian NHS register</td>
<td>4600</td>
<td>34.9% (36.3%)</td>
<td>45.0%</td>
<td>&gt;25 (55)</td>
<td>♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To determine the population prevalence of FM</td>
</tr>
<tr>
<td>Aggarwal et al</td>
<td>Cross-sectional</td>
<td>1 GP practice in Manchester</td>
<td>4200</td>
<td>59.6% (72.0%)</td>
<td>45% (1035)</td>
<td>18–75 (Mdn=48)</td>
<td>♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To investigate the co-occurrence, in the general population, of syndromes that are frequently unexplained</td>
</tr>
<tr>
<td>Parsons et al</td>
<td>Cross-sectional</td>
<td>16 GP practices across SE England</td>
<td>4171</td>
<td>60% (62.0%)</td>
<td>44.0% (1073)</td>
<td>18–102 (52)</td>
<td>♦ ♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To measure the prevalence and troublesomeness of musculoskeletal pain in different body locations and age groups</td>
</tr>
<tr>
<td>Macfarlane et al</td>
<td>Cross-sectional</td>
<td>3 GP practices across NW England</td>
<td>3950</td>
<td>69.9% (80.3%)</td>
<td>41.1% (1020)</td>
<td>25–65 (Mdn=54)</td>
<td>♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To determine whether the report of pain is influenced by meteorological conditions</td>
</tr>
<tr>
<td>Macfarlane et al</td>
<td>Cross-sectional</td>
<td>1 GP practice in Manchester</td>
<td>3004</td>
<td>65.0% (75.0%)</td>
<td>42.8% (835)</td>
<td>18–65</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To determine whether psychological symptoms and mental disorder are an intrinsic part of the CWP syndrome</td>
</tr>
<tr>
<td>Mallen et al</td>
<td>Cross-sectional</td>
<td>3 GP practices in North Staffordshire</td>
<td>2389</td>
<td>35.9% (37.0%)</td>
<td>–</td>
<td>18–25</td>
<td>♦ ♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To establish the prevalence of severely disabling CP in young adults</td>
</tr>
<tr>
<td>Croft et al</td>
<td>Cross-sectional</td>
<td>2 GP practices in Cheshire</td>
<td>2034</td>
<td>66% (75.0%)</td>
<td>43.0% (572)</td>
<td>20–85 (Mdn=46)</td>
<td>♦ ♦</td>
<td>Postal questionnaire</td>
<td>Moderate</td>
<td>To establish the prevalence of CWP and associated symptoms in a general population sample</td>
</tr>
</tbody>
</table>

*Population sample is a duplicate from Elliot et al; therefore, only age-stratified prevalence estimates have been included. Response rates were adjusted to reflect the viable survey denominator.
†=population responded (denominator not stated).
CP, chronic pain; CPG, chronic pain grade; CWP, chronic widespread pain; FM, fibromyalgia; GP, general practitioner; Mdn, median; n, number; NeP, neuropathic pain; NHS, National Health Service.
<table>
<thead>
<tr>
<th>Study</th>
<th>Pain definition</th>
<th>Sample size (response)</th>
<th>Male (n)</th>
<th>Age range (mean)</th>
<th>Prevalence total (95% CI) (n)</th>
<th>Prevalence in males (95% CI)</th>
<th>Prevalence in females (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies excluded from meta-analysis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smith et al[^23]</td>
<td>Aches or pains in previous 1/12, lasting &gt;3/12</td>
<td>11 797 (85.4%)</td>
<td>0%</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>38.40%</td>
</tr>
<tr>
<td>Mallen et al[^24]</td>
<td>Cross-sectional</td>
<td>2389 (37.0%)</td>
<td>–</td>
<td>18–25</td>
<td>14.3% (119)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vandenkerkhof et al[^23]</td>
<td>Aches or pains in previous 1/12, lasting &gt;3/12</td>
<td>8572*</td>
<td>–</td>
<td>45 (45)</td>
<td>53.3% (4573)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Studies reporting data from 1990 to 2000</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croft et al[^27]</td>
<td>Pain in previous 1/12, lasting &gt;3/12</td>
<td>2034 (75.0%)</td>
<td>43.0% (572)</td>
<td>20–85 (Mdn=46)</td>
<td>35.0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elliott et al[^11]</td>
<td>Current pain or discomfort, present for &gt;3/12</td>
<td>5036 (82.3%)</td>
<td>48.3% (1741)</td>
<td>&gt;25</td>
<td>46.4† (1817)</td>
<td>48.9% (37.0% to 61.4%)</td>
<td>51.8% (41.8% to 61.0%)</td>
</tr>
<tr>
<td><strong>Studies reporting data from 2001 to 2009</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torrance et al[^30]</td>
<td>Current pain or discomfort, present for &gt;3/12</td>
<td>6000 (52.4%)</td>
<td>44.4% (1333)</td>
<td>18–96 (50)</td>
<td>48.0% (1420)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parsons et al[^32]</td>
<td>Current pain, present for &gt;3/12</td>
<td>4171 (62.0%)</td>
<td>44.0% (1073)</td>
<td>18–102 (52)</td>
<td>39.5%† (966)</td>
<td>37.2%‡</td>
<td>41.3%‡</td>
</tr>
<tr>
<td><strong>Studies reporting data from 2010 to 2015</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beasley et al[^26]</td>
<td>Pain lasting &gt;3/12</td>
<td>–</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Torrance et al[^29]</td>
<td>Currently troubled by pain or discomfort, present for &gt;3/12</td>
<td>10 000 (47.0%)</td>
<td>42.9% (1846)</td>
<td>&gt;18 (53)</td>
<td>46.6† (2202)</td>
<td>45.0%§</td>
<td>47.9%§</td>
</tr>
<tr>
<td>Bridges[^7]</td>
<td>Current pain, present for &gt;3/12</td>
<td>8599 (66.0%)</td>
<td>44.4% (3817)</td>
<td>16–100</td>
<td>37.2% (3202)</td>
<td>31.0%</td>
<td>37.0%</td>
</tr>
</tbody>
</table>

* = population responded (denominator not stated).
† = Age-adjusted/gender-adjusted estimate. Three gender estimates were calculated from a smaller data set of 4306 participants.
‡ = Presented figures have been derived from tabulated data presented in article.
§ = Gender estimates were calculated from a smaller data set of 4306 participants.

Mdn, median; n, number.
population. Combining these two groups, between 10.4% and 14.3% of the population of the UK report severely disabling chronic pain that is either moderately or severely limiting (Von Korff grades III and IV). One article presented data on chronic neuropathic pain severity estimating 1.8% and 2.6% of the population experience grades III and IV chronic neuropathic pain, respectively.29

Chronic widespread pain

Ten studies presented prevalence data for chronic widespread pain. Four studies surveying age-restricted birth cohorts of the British population,23 31 33 34 and one study reporting estimates from a gender-restricted cohort38 were excluded from the pooled analysis. The remaining five articles reported data on samples representative of the general population from various regions.
across the UK. Prevalence estimates from all 10 studies are reproduced in Table 4, and a forest plot demonstrating the variability among study estimates is displayed in Figure 4 (I² 91.5%, p=0.00). The reported prevalence of chronic widespread pain ranged from 11.2% to 16.5% (pooled estimate 14.2%, 95% CI 12.3% to 16.1%). Prevalence estimates were again higher in female (12.3% to 17.9%) than in male participants (9.0% to 14.1%).

Chronic neuropathic pain
Two studies, from the selection presenting data on chronic pain, also screened participants for features predictive of neuropathic pain (defined as a score of 12, or greater, on Leeds Assessment of Neuropathic Symptoms and Signs questionnaire), thereby collectively estimating the prevalence of chronic neuropathic pain among 16 000 residents registered at general practitioner surgeries across England and Scotland: 8.9% and 8.2% in the respective studies. Estimates for chronic neuropathic pain prevalence were higher in female participants (9.2% to 10.2%) than in males (6.7% to 7.9%).

Fibromyalgia
Owing to the practical restrictions of formally diagnosing a patient with fibromyalgia (requiring a history and examination in order to exclude alternative causes for widespread pain), only one study was able to provide comprehensive data from populations representative of the general population. This study used the modification of the ACR (2010) preliminary diagnostic criteria for fibromyalgia which relies on self-reported pain and somatic symptoms and was developed specifically for epidemiological studies. The authors estimated the population prevalence of fibromyalgia to be 5.4% (95% CI 4.7% to 6.1%). A small proportion of respondents to the survey (2.4% of the source population) were invited for clinical examinations in order to ascertain prevalence rates of fibromyalgia using the conventional diagnostic criteria developed in 1990. These figures were weighted back to the target population in order to generate ‘general population’ estimates, against which the modified research criteria could be compared. However, as the methodology used to generate the latter prevalence estimates was subject to a greater risk of bias, only figures based on the modified criteria, and derived from the source population, have been included in our review.

DISCUSSION
Based on best quality studies of general population samples, the estimated prevalence of chronic pain in the

<table>
<thead>
<tr>
<th>Study</th>
<th>Pain measure</th>
<th>CPGS grade III (%)</th>
<th>CPGS grade III by gender</th>
<th>CPGS grade IV (95% CI)</th>
<th>CPGS grade IV by gender (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith et al</td>
<td>Chronic pain</td>
<td>–</td>
<td>–</td>
<td>6.3% (5.9% to 6.7%)</td>
<td>M=5.7% (4.6% to 6.8%)</td>
</tr>
<tr>
<td>Torrance et al</td>
<td>Chronic pain</td>
<td>6.2</td>
<td>–</td>
<td>6.0%</td>
<td>F=6.9% (5.7% to 8.1%)</td>
</tr>
<tr>
<td>Parsons et al</td>
<td>Chronic pain</td>
<td>6.5</td>
<td>–</td>
<td>7.8%</td>
<td>–</td>
</tr>
<tr>
<td>Bridges†</td>
<td>Chronic pain</td>
<td>4.7</td>
<td>M=3.9%</td>
<td>7.2%</td>
<td>M=6.5%</td>
</tr>
<tr>
<td>Torrance et al</td>
<td>Neuropathic pain</td>
<td>1.8</td>
<td>–</td>
<td>2.6%</td>
<td>F=7.7%</td>
</tr>
</tbody>
</table>

*Estimates adjusted to sampling frame.
†Gender-stratified prevalence estimates from Bridges have been retrieved by access to the raw data.CPGS, Chronic Pain Grade Scale; F, Female; M, Male.
UK is 43%. This equates to just under 28 million people (referencing population statistics from 2013). Chronic pain prevalence rises steadily with increasing age, affecting up to 62% of the population over the age of 75, suggesting that the burden of chronic pain may increase further still, in line with an ageing population, if the incidence remains unaltered. The proportion of patients reporting severe pain was also summarised. Weighted averages for chronic widespread pain suggest that 14.2% of the population may be affected. Between 10.4% and 14.3% of the population report chronic pain that is either moderately or severely limiting (Von Korff grades III and IV), figures that translate into an estimated median of 7.9 million people in the UK population with this category of chronic pain.

The estimate of 43% (28 million people) in the UK with chronic pain is considerably higher than a previously quoted figure of 7.8 million people with ‘chronic pain’ based on data from the telephone-based pain in Europe survey. However, the European survey looked only at moderate-to-severe pain, and figures from that survey are more directly comparable with, and similar to, our summary estimates for moderately or severely limiting chronic pain.

Chronic pain in our review was defined primarily in terms of symptom duration (pain present for a period of 3 months or greater), arguably not reflective of the societal burden of the condition. It may be that a proportion of ‘chronic pain’ reporters are highly functioning individuals with little restriction of day-to-day activity, and limited reliance on health services; many people living with chronic inflammatory or degenerative conditions, in their mildest forms, would fall into this category. However, it is of interest that even in the youngest population age groups, where these conditions are likely to be rare, prevalence estimates for chronic pain are as high as 30% (Figure 3), suggesting a greater potential burden on the ‘working’ population than anticipated.

To our knowledge, this is the first study attempting to synthesise prevalence data on chronic pain phenotypes specifically from the UK. In order to strengthen our findings, we have attempted to limit the impact of clinical and methodological heterogeneity by imposing fairly strict selection criteria from the outset of our review, and by remaining selective about the studies that were permitted to enter the meta-analysis. At the expense of sensitivity, our selection criteria generated data comparable enough to allow for synthesis and meta-analysis of the two most prominent pain phenotypes (chronic pain and chronic widespread pain). The tests for statistical heterogeneity among articles included in the meta-analyses still demonstrated substantial variability between studies however ($I^2$ 98.9% and 95.2% for chronic pain and chronic widespread pain, respectively). There was limited opportunity to investigate sources of this variability due to the small number of studies included and the lack of recorded characteristics showing variability between studies. A
stratified analysis grouped by calendar year of survey suggested this as one potential source of systematic variation between studies, prevalence increasing with time, and one grouping studies by location of study population suggested this as another potential source, but firm conclusions in this regard are limited by the few studies available in which to make robust comparisons, and the marked heterogeneity within the groups. No other stratified analyses by study were possible, but we can speculate that differences in age structure, levels of deprivation and urban/rural differences could also be contributing to differences between study populations, as well as variation in the distribution of known risk factors and confounders. However, without access to individual patient data, and an individual participant data meta-analysis, it is not possible to control fully for these factors.

Another limitation of our review was the quality of the studies available for synthesis. Fewer than half of the 19 included studies were primarily designed to produce prevalence data (table 1), and this was reflected in the variability of reporting of important variables: population denominators and response rates were not always identifiable, in particular where the survey measured multiple outcomes; participant demographics were not always displayed; and there were occasional numerical discrepancies between the data presented in the study abstract, main text and results tables. Six studies were excluded from the review on the grounds of a higher than acceptable risk of bias, three of which provided data that could potentially have been incorporated into our meta-analysis of chronic pain prevalence. We acknowledge that different approaches exist, in terms of whether to, and if so how to, use quality appraisal in systematic literature reviews. However, our a priori approach was that quality assessment would be used to select only those studies that met a minimum standard.

While it is possible that references from the grey literature have been missed, we are reassured that a recent systematic review of all chronic widespread pain surveys did not identify any eligible UK papers which had not been included at some stage of a literature search.

Our study indicates how a systematic review of published surveys carried out in one country, with exclusion of studies at high risk of bias, can provide population prevalence estimates for different pain conditions of the sort required by national policy strategies for prevention and care of chronic pain. Despite the high level of heterogeneity between study estimates, the summary figures are comparable with those from international surveys and reviews. For example in the USA, the Institute of Medicine estimated the prevalence of chronic pain in America to be 40%, affecting an estimated 100 million people, similar to those of WHO surveys across developed (37%) and developing (41%) countries, despite between-country variability, and to the estimate from our review here (43%). Surveys of more severe chronic disabling pain in America, Europe and elsewhere estimate similar prevalence figures to those found here (around 12%). We conclude that our estimates can be used in national and local prevalence calculations of chronic pain prevalence, to inform, for example, planning of community pain services and targets for prevention.

In conclusion, we have used the best available data to demonstrate that chronic pain affects between one-third and one-half of the population of the UK: a figure that is likely to increase further, with time, in line with an ageing population. Such prevalence data does not itself define need for care or targets for prevention, but reliable information on prevalence will help to drive public health and healthcare policymakers’ prioritisation of

Figure 4  Pooled estimates for chronic widespread pain prevalence.
this important cause of distress and disability in the general population. In the interests of improving the quality and reporting of epidemiological data, we would encourage future population studies to adhere to standardised methods for collecting and presenting observational data, such as the guidance produced by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) group.48

Acknowledgements The authors are grateful for the input of Professor Blair Smith (University of Dundee): his counsel early in the project, and his advice and comments regarding the search strategy; and Professor Danielle van der Windt (Keel University) for helpful advice and comments.

Contributors AF was involved with the study design, data collection, analysis and write-up. He is the guarantor. GTJ and PC assisted with the study design, data collection, analysis and revisions. RML and LJJD contributed to the design of the study and revisions to the article.

Funding The British Pain Society provided financial assistance to AF with the costs of this project. PC was partly supported by an Arthritis Research UK Primary Care Centre grant (reference: 18139).

Competing interests RML reports personal fees from Grunenthal, grants and personal fees from Napp/Mundipharma, personal fees from Pfizer, personal fees from Astrazeneca, personal fees from Biocloud, Sinehai, personal fees from The Medicines Co, outside the submitted work.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


